With an up close look at the cancer treatment process, Lefkofsky was dismayed by how little patient care was informed by modern technology. From his viewpoint, there was a hole in cancer research.
In 2015, Lefkofsky founded Tempus Technologies; a Chicago based company which developed a software data platform that analyzes large volumes of molecular and clinical data. With his team of roughly 150 biologists, geneticists and immunologists working closely with scientists and engineers, they’re seeking the answer to this question; “Why do some patients respond well to cancer therapy while others don’t?”
With an FDA approved immunotherapy for treating cancers with specific genomic profiles. This marks the first time an agency has used genomic profiles rather than anatomical tumors; which is the criterion for the drug approval process.
While it’s still uncertain why some patients respond well to cancer therapies and others don’t, it’s believed that by combining the patient’s genomic and clinical data is the key to determining which cancer therapies should be used. That’s why Tempus Technologies collect massive amount of data through partnerships with hospitals and academic institutes.
Tempus bridges the gap and helps doctors make more informed decisions concerning patient therapies. This platform provides doctors with tools to help them provide personalized care and treatments. Lefkofsky and his team are still fine tuning this end to an end analytics platform, which provides real time information to doctors. This information connects them with both clinical and molecular data.
Eric Lefkofsky, philanthropist and his wife founded the Lefkofsky Family Foundation in 2006. Lefkofsky serves on the Board of Trustees at Luree’s Children’s Hospital of Chicago. He believes that these four causes could use extra attention: education, human rights, civic causes, and medical discoveries. However, he spends most of his time and focus on medical discoveries through his research at Tempus.
Details Eric: Facebook.com/eplefkofsky/